Campbell & Co Investment Adviser’s Denali Therapeutics DNLI Stock Holding History

Campbell & Co Investment Adviser’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-216,774	Closed	-$3.15M	–	1190
2025 Q3	$3.15M	Buy	216,774 +74,066	+52%	+$1.06M	0.24%	92
2025 Q2	$2M	Buy	142,708 +74,523	+109%	+$1.05M	0.13%	249
2025 Q1	$927K	Buy	68,185 +30,500	+81%	+$584K	0.07%	461
2024 Q4	$768K	Buy	+37,685	New	+$965K	0.06%	501
2024 Q1	–	Sell	-65,105	Closed	-$1.4M	–	1159
2023 Q4	$1.4M	Buy	65,105 +47,847	+277%	+$948K	0.13%	243
2023 Q3	$356K	Buy	+17,258	New	+$438K	0.04%	655
2023 Q2	–	Sell	-9,005	Closed	-$207K	–	943
2023 Q1	$207K	Buy	+9,005	New	+$248K	0.04%	726

Other funds holding DNLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Campbell & Co Investment Adviser's DNLI Position: Q4 2025 in Review

Campbell & Co Investment Adviser sold out of Denali Therapeutics (DNLI) in Q4 2025, closing a stake of 216,774 shares — an estimated $3.15M sold.

Campbell & Co Investment Adviser first reported a position in DNLI in Q1 2023 and held it in 7 quarters. The position peaked at $3.15M in Q3 2025. 250 funds tracked by Wall St. Rank hold DNLI as of Q4 2025.

Campbell & Co Investment Adviser reported no remaining Denali Therapeutics position as of Q4 2025 after selling out during the quarter.
Campbell & Co Investment Adviser sold 216,774 Denali Therapeutics shares in Q4 2025, an estimated $3.15M.
Campbell & Co Investment Adviser first reported a position in Denali Therapeutics in Q1 2023 and held it in 7 quarters.
Campbell & Co Investment Adviser's Denali Therapeutics position peaked at $3.15M in Q3 2025.
250 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2025.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2025, filed 12 Feb 2026.